VXRT - Vaxart, Inc.
0.3765 -0.00 (-0.13%)
After hours: 4:13PM EDT
| Previous Close | 0.3760 |
| Open | 0.3900 |
| Bid | 0.3531 x 1800 |
| Ask | 0.3798 x 2200 |
| Day's Range | 0.3725 - 0.3900 |
| 52 Week Range | 0.2500 - 5.0000 |
| Volume | 298,768 |
| Avg. Volume | 639,315 |
| Market Cap | 14.459M |
| Beta (3Y Monthly) | 0.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0330 |
| Earnings Date | Aug 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2012-11-09 |
| 1y Target Est | 4.00 |
- GuruFocus.com
Largest Insider Trades of the Week
Mark Zuckerberg sheds shares of Facebook Continue reading...
- GlobeNewswire
Vaxart to Present Clinical Data From its Norovirus Phase 1b Study at Three Global Healthcare Conferences in October 2019
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by.
- GlobeNewswire
Vaxart Announces Pricing of $8 Million Underwritten Public Offering
Vaxart, Inc. (VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public offering of 26,666,667 shares of common stock (which includes pre-funded warrants to purchase up to an aggregate of 4,100,000 shares of common stock in lieu thereof), and common warrants to purchase up to an aggregate of 26,666,667 shares of common stock. Each share of common stock and, as applicable, pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.30.
- GlobeNewswire
Vaxart’s Tableted Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study
Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced positive topline results from the randomized, double-blind, placebo-controlled Phase 1b safety, immunogenicity and interference study with its oral tableted bivalent norovirus vaccine in healthy adults. The study met all primary endpoints for safety and demonstrated robust immunogenicity, with 78% - 93% of subjects responding by eliciting IgA antibody secreting cells (ASC), a key marker for mucosal immunity and a potential correlate of protection for norovirus disease.
- Simply Wall St.
Do Institutions Own Vaxart, Inc. (NASDAQ:VXRT) Shares?
If you want to know who really controls Vaxart, Inc. (NASDAQ:VXRT), then you'll have to look at the makeup of its...
- Zacks
Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)
Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.
- Zacks
Endo International Files BLA for Label Expansion of Xiaflex
Endo International (ENDP) files BLA for the additional indication of Xiaflex [collagenase clostridium histolyticum (CCH)] for the treatment of cellulite in the buttocks.
- Business Wire
Vaxart to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company update and overview at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019, at 12:30 p.m. EST in New York. A live webcast of the presentation will be available in the Investors section of Vaxart’s website at investors.vaxart.com. A replay of the webcast will be archived on Vaxart’s website for 30 days following the presentation.
- Simply Wall St.
Those Who Purchased Vaxart (NASDAQ:VXRT) Shares A Year Ago Have A 77% Loss To Show For It
As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...
- Business Wire
Vaxart to Present at ASM Microbe 2019
Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., senior scientist at Vaxart, will present preclinical results of its oral Respiratory Syncytial Virus vaccine in a poster presentation at the American Society of Microbiology 2019, taking place from June 20-24, ...
- Business Wire
New Publication in Vaccine Highlights Preclinical Results of Vaxart’s Mucosal Chikungunya Vaccine
Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the publication of the comprehensive results from a preclinical trial of its chikungunya vaccine in the peer reviewed journal, Vaccine. The article, titled “An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling,” details the results from a study using Vaxart’s chikungunya vaccine candidate in a preclinical efficacy model. “These preclinical results demonstrate that our vaccine candidate induced significant neutralizing antibodies against chikungunya virus as well as protective efficacy against virus-induced pathologic changes,” said Sean Tucker, Ph.D., founder and chief scientific officer of Vaxart.
- Business Wire
Vaxart Announces First Quarter 2019 Financial Results and Provides Corporate Update
- $13 million raised in 1H19 -
- Simply Wall St.
Have Insiders Been Buying Vaxart, Inc. (NASDAQ:VXRT) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We often see insiders buying up shares in companies that perform well over the long term. The flip side...
- Business Wire
Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced it has started dosing subjects in the randomized cohort of the Phase 1b bivalent norovirus vaccine clinical trial. “We are delighted to start the randomized portion of the bivalent norovirus phase 1b trial,” said David Taylor, M.D., chief medical officer of Vaxart. Norovirus is the leading cause of foodborne illness in the United States and causes significant morbidity and mortality in older adults and the very young.
- Business Wire
Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases
Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scientist at Vaxart, will present preclinical data in a poster presentation at the 29th European Congress of Clinical Microbiology and Infectious Diseases showing that Vaxart’s oral quadrivalent influenza vaccine conferred 100% protection against a lethal H5N1 avian influenza challenge in ferrets.
- Business Wire
Vaxart Announces Pricing of Underwritten Public Offering
Vaxart, Inc. (VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public offering of 9,090,010 shares of common stock (which includes pre-funded warrants to purchase up to an aggregate of 8,165,455 shares of common stock in lieu thereof), and common warrants to purchase up to an aggregate of 9,090,010 shares of common stock. Each share of common stock and, as applicable, pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at an effective price to the public of $1.10 per share and accompanying common warrant. Each common warrant will have an exercise price of $1.10 per share, be exercisable immediately and will expire five years from the date of issuance.
- Business Wire
Vaxart to Present at Global Medical Meetings in April
Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced participation in two upcoming global medical meetings in April.
- Business Wire
Vaxart Completes Dosing of the Lead-In Cohort in Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the completion of dosing of the lead-in cohort in the Phase 1b bivalent norovirus vaccine clinical trial with its oral norovirus GII.4 vaccine. The Vaxart bivalent norovirus vaccine consists of an oral norovirus GI.1 vaccine and an oral norovirus GII.4 vaccine administered concurrently by tablet. The bivalent norovirus Phase 1b trial consists of two parts, an open-label lead-in phase which has now been completed, and a randomized, double-blind, placebo-controlled phase which is expected to start in April, subject to final review by the FDA.
- Business Wire
Vaxart Announces Closing of Registered Direct Offering of Common Stock
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of 1,200,000 shares of its common stock at a price of $2.50 per share. Total gross proceeds from the offering were $3.0 million, before deducting placement agent fees and estimated offering expenses. The securities described above were offered by Vaxart pursuant to a registration statement on Form S-3 (File No. 333-228910) previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on March 15, 2019.
- ACCESSWIRE
Watch These Four Healthcare Stocks Set The Pace On Tuesday
Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.
- Business Wire
Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market
Vaxart, Inc. (VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering priced at-the-market of 1,200,000 shares of the Vaxart’s common stock, at a purchase price of $2.50 per share, for aggregate gross proceeds of $3 million. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. The shares of common stock are being offered by Vaxart pursuant to a “shelf” registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC").
- Business Wire
Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the initiation of a Phase 1b bivalent norovirus vaccine clinical trial. “The initiation of the bivalent norovirus vaccine Phase 1b trial marks a significant step towards our goal of developing a vaccine that can protect the most vulnerable patients from this highly infectious disease,” said Wouter Latour, M.D., chief executive officer of Vaxart.
- Business Wire
Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
Initiation of Two Norovirus Vaccine Trials Expected in 1H 2019
